Do analysts recommend EMD or STEX?

Biosig Technologies has a consensus price target of $4.00, indicating a potential upside of 492.07%. Given Biosig Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Biosig Technologies is more favorable than Western Asset Emerging Markets Debt Fund. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Western Asset Emerging Markets Debt Fund 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Biosig Technologies 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, EMD or STEX?

Western Asset Emerging Markets Debt Fund has higher revenue and earnings than Biosig Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Western Asset Emerging Markets Debt Fund $93.58M 2.91 N/A N/A N/A Biosig Technologies $40K 1,967.01 -$462.77M -$9.05 N/A

Is EMD or STEX more profitable?

Western Asset Emerging Markets Debt Fund's return on equity of 0.00% beat Biosig Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Western Asset Emerging Markets Debt Fund N/A N/A N/A Biosig Technologies N/A -462.48% -307.38%

Do analysts rate CUB or STEX?

Biosig Technologies has a consensus target price of $4.00, indicating a potential upside of 492.07%. Given Biosig Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Biosig Technologies is more favorable than Lionheart Holdings Class A Ordinary Shares. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lionheart Holdings Class A Ordinary Shares 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biosig Technologies 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CUB or STEX more profitable?

Lionheart Holdings Class A Ordinary Shares' return on equity of -18.27% beat Biosig Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Lionheart Holdings Class A Ordinary Shares N/A -18.27% 0.73% Biosig Technologies N/A -462.48% -307.38%

Does the media refer more to CUB or STEX?

In the previous week, Lionheart Holdings Class A Ordinary Shares and Lionheart Holdings Class A Ordinary Shares both had 3 articles in the media. Lionheart Holdings Class A Ordinary Shares' average media sentiment score of 1.59 beat Biosig Technologies' score of 0.61 indicating that Lionheart Holdings Class A Ordinary Shares is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lionheart Holdings Class A Ordinary Shares 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Biosig Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SAR or STEX?

In the previous week, Saratoga Investment had 5 more articles in the media than Biosig Technologies. MarketBeat recorded 8 mentions for Saratoga Investment and 3 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 0.61 beat Saratoga Investment's score of 0.32 indicating that Biosig Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Saratoga Investment 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biosig Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer STEX or EVOX?

Biosig Technologies currently has a consensus price target of $4.00, suggesting a potential upside of 492.07%. Given Biosig Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe Biosig Technologies is more favorable than Evolution Global Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biosig Technologies 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Evolution Global Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, STEX or EVOX?

Evolution Global Acquisition has lower revenue, but higher earnings than Biosig Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biosig Technologies $40K 1,967.01 -$462.77M -$9.05 N/A Evolution Global Acquisition N/A N/A N/A N/A N/A

Is STEX or EVOX more profitable?

Evolution Global Acquisition's return on equity of 0.00% beat Biosig Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Biosig Technologies N/A -462.48% -307.38% Evolution Global Acquisition N/A N/A N/A

Do analysts prefer TVA or STEX?

Biosig Technologies has a consensus price target of $4.00, indicating a potential upside of 492.07%. Given Biosig Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Biosig Technologies is more favorable than Texas Ventures Acquisition III. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Texas Ventures Acquisition III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biosig Technologies 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, TVA or STEX?

Texas Ventures Acquisition III has higher earnings, but lower revenue than Biosig Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Texas Ventures Acquisition III N/A N/A N/A N/A N/A Biosig Technologies $40K 1,967.01 -$462.77M -$9.05 N/A

Is TVA or STEX more profitable?

Texas Ventures Acquisition III's return on equity of 0.00% beat Biosig Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Texas Ventures Acquisition III N/A N/A N/A Biosig Technologies N/A -462.48% -307.38%

Biosig Technologies (STEX) Competitors

$0.68 -0.03 (-4.14%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$0.68 0.00 (-0.09%)

As of 09/29/2026 07:53 PM Eastern

Compare

STEX vs. EMD, CUB, SAR, EVOX, and TVA

Should you buy Biosig Technologies stock or one of its competitors? Biosig Technologies's main competitors and comparable companies include Western Asset Emerging Markets Debt Fund (EMD), Lionheart Holdings Class A Ordinary Shares (CUB), Saratoga Investment (SAR), Evolution Global Acquisition (EVOX), and Texas Ventures Acquisition III (TVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does Biosig Technologies compare to Western Asset Emerging Markets Debt Fund?

Western Asset Emerging Markets Debt Fund (NYSE:EMD) and Biosig Technologies (NASDAQ:STEX) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Western Asset Emerging Markets Debt Fund had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 4 mentions for Western Asset Emerging Markets Debt Fund and 3 mentions for Biosig Technologies. Western Asset Emerging Markets Debt Fund's average media sentiment score of 1.16 beat Biosig Technologies' score of 0.61 indicating that Western Asset Emerging Markets Debt Fund is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Western Asset Emerging Markets Debt Fund	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biosig Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

33.0% of Western Asset Emerging Markets Debt Fund shares are held by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are held by institutional investors. 1.0% of Western Asset Emerging Markets Debt Fund shares are held by company insiders. Comparatively, 52.7% of Biosig Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Western Asset Emerging Markets Debt Fund's return on equity of 0.00% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Western Asset Emerging Markets Debt Fund	N/A	N/A	N/A
Biosig Technologies	N/A	-462.48%	-307.38%

Western Asset Emerging Markets Debt Fund has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Biosig Technologies has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market.

Western Asset Emerging Markets Debt Fund has higher revenue and earnings than Biosig Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Western Asset Emerging Markets Debt Fund	$93.58M	2.91	N/A	N/A	N/A
Biosig Technologies	$40K	1,967.01	-$462.77M	-$9.05	N/A

Biosig Technologies has a consensus price target of $4.00, indicating a potential upside of 492.07%. Given Biosig Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Biosig Technologies is more favorable than Western Asset Emerging Markets Debt Fund.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Western Asset Emerging Markets Debt Fund	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Western Asset Emerging Markets Debt Fund and Biosig Technologies tied by winning 6 of the 12 factors compared between the two stocks.

How does Biosig Technologies compare to Lionheart Holdings Class A Ordinary Shares?

Lionheart Holdings Class A Ordinary Shares (NASDAQ:CUB) and Biosig Technologies (NASDAQ:STEX) are both small-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Biosig Technologies has a consensus target price of $4.00, indicating a potential upside of 492.07%. Given Biosig Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Biosig Technologies is more favorable than Lionheart Holdings Class A Ordinary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lionheart Holdings Class A Ordinary Shares	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lionheart Holdings Class A Ordinary Shares has higher earnings, but lower revenue than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Lionheart Holdings Class A Ordinary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lionheart Holdings Class A Ordinary Shares	N/A	N/A	$8.95M	$0.06	181.67
Biosig Technologies	$40K	1,967.01	-$462.77M	-$9.05	N/A

Lionheart Holdings Class A Ordinary Shares has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Biosig Technologies has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market.

In the previous week, Lionheart Holdings Class A Ordinary Shares and Lionheart Holdings Class A Ordinary Shares both had 3 articles in the media. Lionheart Holdings Class A Ordinary Shares' average media sentiment score of 1.59 beat Biosig Technologies' score of 0.61 indicating that Lionheart Holdings Class A Ordinary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lionheart Holdings Class A Ordinary Shares	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Biosig Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.2% of Biosig Technologies shares are owned by institutional investors. 25.0% of Lionheart Holdings Class A Ordinary Shares shares are owned by insiders. Comparatively, 52.7% of Biosig Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lionheart Holdings Class A Ordinary Shares' return on equity of -18.27% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lionheart Holdings Class A Ordinary Shares	N/A	-18.27%	0.73%
Biosig Technologies	N/A	-462.48%	-307.38%

Summary

Biosig Technologies beats Lionheart Holdings Class A Ordinary Shares on 7 of the 13 factors compared between the two stocks.

How does Biosig Technologies compare to Saratoga Investment?

Saratoga Investment (NYSE:SAR) and Biosig Technologies (NASDAQ:STEX) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

19.1% of Saratoga Investment shares are held by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are held by institutional investors. 10.6% of Saratoga Investment shares are held by company insiders. Comparatively, 52.7% of Biosig Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Saratoga Investment had 5 more articles in the media than Biosig Technologies. MarketBeat recorded 8 mentions for Saratoga Investment and 3 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 0.61 beat Saratoga Investment's score of 0.32 indicating that Biosig Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Saratoga Investment	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biosig Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Saratoga Investment has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Biosig Technologies has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market.

Saratoga Investment has a net margin of 12.70% compared to Biosig Technologies' net margin of 0.00%. Saratoga Investment's return on equity of 8.76% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Saratoga Investment	12.70%	8.76%	2.95%
Biosig Technologies	N/A	-462.48%	-307.38%

Saratoga Investment has higher revenue and earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Saratoga Investment, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Saratoga Investment	$28.31M	9.68	$36.60M	$1.00	17.05
Biosig Technologies	$40K	1,967.01	-$462.77M	-$9.05	N/A

Saratoga Investment currently has a consensus target price of $21.50, suggesting a potential upside of 26.09%. Biosig Technologies has a consensus target price of $4.00, suggesting a potential upside of 492.07%. Given Biosig Technologies' higher possible upside, analysts clearly believe Biosig Technologies is more favorable than Saratoga Investment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Saratoga Investment	0 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Saratoga Investment beats Biosig Technologies on 9 of the 15 factors compared between the two stocks.

How does Biosig Technologies compare to Evolution Global Acquisition?

Biosig Technologies (NASDAQ:STEX) and Evolution Global Acquisition (NASDAQ:EVOX) are both small-cap finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Evolution Global Acquisition's return on equity of 0.00% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-462.48%	-307.38%
Evolution Global Acquisition	N/A	N/A	N/A

Evolution Global Acquisition has lower revenue, but higher earnings than Biosig Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	1,967.01	-$462.77M	-$9.05	N/A
Evolution Global Acquisition	N/A	N/A	N/A	N/A	N/A

Biosig Technologies currently has a consensus price target of $4.00, suggesting a potential upside of 492.07%. Given Biosig Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe Biosig Technologies is more favorable than Evolution Global Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evolution Global Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Biosig Technologies had 2 more articles in the media than Evolution Global Acquisition. MarketBeat recorded 3 mentions for Biosig Technologies and 1 mentions for Evolution Global Acquisition. Evolution Global Acquisition's average media sentiment score of 1.82 beat Biosig Technologies' score of 0.61 indicating that Evolution Global Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Biosig Technologies	Positive
Evolution Global Acquisition	Very Positive

7.2% of Biosig Technologies shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Biosig Technologies beats Evolution Global Acquisition on 7 of the 10 factors compared between the two stocks.

How does Biosig Technologies compare to Texas Ventures Acquisition III?

Texas Ventures Acquisition III (NASDAQ:TVA) and Biosig Technologies (NASDAQ:STEX) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, Biosig Technologies had 2 more articles in the media than Texas Ventures Acquisition III. MarketBeat recorded 3 mentions for Biosig Technologies and 1 mentions for Texas Ventures Acquisition III. Texas Ventures Acquisition III's average media sentiment score of 1.82 beat Biosig Technologies' score of 0.61 indicating that Texas Ventures Acquisition III is being referred to more favorably in the media.

Company	Overall Sentiment
Texas Ventures Acquisition III	Very Positive
Biosig Technologies	Positive

Texas Ventures Acquisition III has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Biosig Technologies has a beta of 2.01, suggesting that its stock price is 101% more volatile than the broader market.

7.2% of Biosig Technologies shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Texas Ventures Acquisition III has higher earnings, but lower revenue than Biosig Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Texas Ventures Acquisition III	N/A	N/A	N/A	N/A	N/A
Biosig Technologies	$40K	1,967.01	-$462.77M	-$9.05	N/A

Texas Ventures Acquisition III's return on equity of 0.00% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Texas Ventures Acquisition III	N/A	N/A	N/A
Biosig Technologies	N/A	-462.48%	-307.38%

Biosig Technologies has a consensus price target of $4.00, indicating a potential upside of 492.07%. Given Biosig Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Biosig Technologies is more favorable than Texas Ventures Acquisition III.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Texas Ventures Acquisition III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Biosig Technologies beats Texas Ventures Acquisition III on 8 of the 11 factors compared between the two stocks.

Get Biosig Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STEX vs. The Competition

Export

Metric	Biosig Technologies	Capital Markets Industry	Finance Sector	NASDAQ Exchange
Market Cap	$82.08M	$5.20B	$13.59B	$13.05B
Dividend Yield	N/A	7.52%	6.00%	14.18%
P/E Ratio	-0.07	29.05	24.31	25.68
Price / Sales	1,967.01	1,193.68	506.20	85.12
Price / Cash	N/A	47.83	50.23	52.35
Price / Book	0.81	3.50	2.70	6.34
Net Income	-$462.77M	$417.69M	$1.32B	$360.56M
7 Day Performance	-18.98%	-0.91%	-0.84%	-1.59%
1 Month Performance	-12.46%	4.91%	1.06%	-4.08%
1 Year Performance	N/A	3.86%	8.36%	3.79%

Biosig Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STEX Biosig Technologies	3.0074 of 5 stars	$0.68 -4.1%	$4.00 +492.1%	N/A	$82.08M	$40K	N/A	50
EMD Western Asset Emerging Markets Debt Fund	N/A	$10.02 +0.2%	N/A	-7.2%	$286.87M	$93.58M	N/A	N/A	News Coverage Positive News Short Interest Decrease
CUB Lionheart Holdings Class A Ordinary Shares	1.0915 of 5 stars	$10.87 flat	N/A	+3.7%	$284.39M	N/A	181.20	3	News Coverage Positive News Short Interest Decrease
SAR Saratoga Investment	4.4705 of 5 stars	$17.55 -0.5%	$21.50 +22.5%	-29.5%	$283.67M	$125.71M	17.55	3,211	Upcoming Earnings
EVOX Evolution Global Acquisition	N/A	$10.13 +0.2%	N/A	N/A	$283.08M	N/A	N/A	2	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STEX) was last updated on 9/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biosig Technologies (STEX) Competitors

STEX vs. EMD, CUB, SAR, EVOX, and TVA

How does Biosig Technologies compare to Western Asset Emerging Markets Debt Fund?

Summary

How does Biosig Technologies compare to Lionheart Holdings Class A Ordinary Shares?

Summary

How does Biosig Technologies compare to Saratoga Investment?

Summary

How does Biosig Technologies compare to Evolution Global Acquisition?

Summary

How does Biosig Technologies compare to Texas Ventures Acquisition III?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STEX vs. The Competition

Biosig Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biosig Technologies (STEX) Competitors

STEX vs. EMD, CUB, SAR, EVOX, and TVA

How does Biosig Technologies compare to Western Asset Emerging Markets Debt Fund?

Does the media refer more to EMD or STEX?

Do institutionals and insiders believe in EMD or STEX?

Is EMD or STEX more profitable?

Which has more risk & volatility, EMD or STEX?

Which has preferable earnings and valuation, EMD or STEX?

Do analysts recommend EMD or STEX?

Summary

How does Biosig Technologies compare to Lionheart Holdings Class A Ordinary Shares?

Do analysts rate CUB or STEX?

Which has preferable valuation & earnings, CUB or STEX?

Which has more volatility and risk, CUB or STEX?

Does the media refer more to CUB or STEX?

Do insiders and institutionals believe in CUB or STEX?

Is CUB or STEX more profitable?

Summary

How does Biosig Technologies compare to Saratoga Investment?

Do institutionals and insiders have more ownership in SAR or STEX?

Does the media favor SAR or STEX?

Which has more risk & volatility, SAR or STEX?

Is SAR or STEX more profitable?

Which has stronger earnings and valuation, SAR or STEX?

Do analysts recommend SAR or STEX?

Summary

How does Biosig Technologies compare to Evolution Global Acquisition?

Is STEX or EVOX more profitable?

Which has better earnings and valuation, STEX or EVOX?

Do analysts prefer STEX or EVOX?

Does the media favor STEX or EVOX?

Do institutionals and insiders hold more shares of STEX or EVOX?

Summary

How does Biosig Technologies compare to Texas Ventures Acquisition III?

Does the media favor TVA or STEX?

Which has more volatility and risk, TVA or STEX?

Do institutionals and insiders have more ownership in TVA or STEX?

Which has stronger valuation and earnings, TVA or STEX?

Is TVA or STEX more profitable?

Do analysts prefer TVA or STEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STEX vs. The Competition

Biosig Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools